Ethic Inc’s PTC Therapeutics PTCT Stock Holding History

Ethic Inc’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$471K	Buy	5,779 +276	+5%	+$19.9K	0.01%	963
2026 Q1	$375K	Buy	5,503 +1,206	+28%	+$85.4K	0.01%	975
2025 Q4	$326K	Buy	+4,297	New	+$312K	0.01%	974

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Ethic Inc's PTCT Position: Q2 2026 in Review

Ethic Inc increased its PTC Therapeutics (PTCT) stake by 5% in Q2 2026, buying an estimated $19.9K and bringing the position to 5,779 shares worth $471K. The position accounts for 0.01% of the portfolio, ranked #963.

Ethic Inc first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Ethic Inc held 5,779 shares of PTC Therapeutics worth $471K as of Q2 2026.
Ethic Inc bought 276 PTC Therapeutics shares in Q2 2026, an estimated $19.9K.
PTC Therapeutics made up 0.01% of Ethic Inc's portfolio in Q2 2026, its #963 holding.
Ethic Inc first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.